An ambitious new international collaboration, bolstered by a prestigious pan-European EUREKA grant, is set to revolutionize the treatment landscape for hyper-inflammatory diseases, including inflammatory bowel disease (IBD), by developing highly targeted small-molecule therapies. This groundbreaking initiative, announced on February 11 by Evogene (Nasdaq: EVGN), Systasy Bioscience, and LMU University Hospital Munich, with crucial participation from the Weizmann Institute of Science, aims to address a significant unmet therapeutic need by focusing on dysregulated neutrophil activity. The partnership strategically integrates cutting-edge AI-powered molecular design, advanced iPSC-based functional profiling, and deep clinical expertise in rare immunodeficiencies to forge a new path in precision medicine.
The Pervasive Challenge of Hyper-Inflammatory Diseases
Inflammatory diseases represent a vast and growing global health burden, affecting hundreds of millions of people worldwide. Conditions such as inflammatory bowel disease (IBD), which encompasses Crohn’s disease and ulcerative colitis, are characterized by chronic inflammation that can lead to severe tissue damage, debilitating symptoms, and a significantly diminished quality of life. Global prevalence estimates for IBD varied, but widely cited analyses in 2017 placed the figure at approximately 6.8 million, with a concerning upward trend observed in newly industrialized countries, suggesting environmental and lifestyle factors contribute to their rising incidence. Beyond IBD, a myriad of other autoimmune and inflammatory conditions, from rheumatoid arthritis to psoriasis, share underlying pathogenic mechanisms often involving an overactive immune response.
Central to many of these conditions are neutrophils, a type of white blood cell that serves as one of the immune system’s first responders to infection and injury. While essential for host defense, dysregulated or excessive neutrophil activity can paradoxically become a key driver of chronic inflammation and tissue destruction. In hyper-inflammatory states, neutrophils can release a barrage of pro-inflammatory mediators, enzymes, and reactive oxygen species, contributing significantly to the pathology seen in diseases like IBD. Despite their critical role, current therapeutic approaches for inflammatory diseases frequently involve broad immune suppression, which, while effective in reducing inflammation, often comes with significant side effects, including increased susceptibility to infections and other adverse events. The partners in this collaboration argue that existing treatments rarely directly and selectively target neutrophil-driven inflammation, leaving a crucial gap in therapeutic options that this initiative aims to fill.
Translating Rare Disease Insights into Broad Therapeutic Strategies
The scientific bedrock of this collaboration is rooted in the pioneering work of Professor Christoph Klein at LMU’s Dr. von Hauner Children’s Hospital. Professor Klein’s research group made a profound discovery by identifying a rare genetic immunodeficiency. Intriguingly, individuals with this specific condition exhibited reduced neutrophil counts, yet remarkably, they did not suffer from significant functional immune impairment. This observation provided a critical natural experiment, demonstrating that it might be possible to modulate neutrophil activity, specifically reducing excessive numbers or function, without broadly compromising the body’s overall immune defenses.
As Professor Klein articulated, "We care for children with rare diseases every day; occasionally, we discover novel genetic defects and elucidate pathomechanisms. Only rarely, however, is clinical and scientific knowledge translated into the development of novel therapeutic strategies." This sentiment underscores the transformative potential of this collaboration: to translate a naturally occurring biological phenomenon observed in a rare patient population into a novel therapeutic strategy applicable to a much wider patient demographic suffering from common inflammatory conditions. The goal is to develop therapies that can precisely modulate excessive neutrophil-driven inflammation, offering a path to more targeted intervention that could potentially bypass the broad immune suppression characteristic of many current treatments. Such an approach could drastically improve patient outcomes by reducing debilitating side effects and enhancing long-term disease management.
A Synergistic Framework: AI, Stem Cells, and Clinical Expertise
The strength of this collaboration lies in the diverse and complementary capabilities brought by each partner, forming a robust pipeline from discovery to translational development.
Evogene (Nasdaq: EVGN), an Israeli computational biology company, takes the lead in the small-molecule discovery efforts. Leveraging its proprietary ChemPass AI generative engine, Evogene will be responsible for designing, optimizing, and prioritizing novel inhibitors. ChemPass AI represents a significant leap in drug discovery, employing advanced algorithms and machine learning to explore vast chemical spaces, predict molecular properties, and identify potential drug candidates with unprecedented speed and accuracy. In an industry where traditional drug discovery is notoriously time-consuming, expensive, and prone to high failure rates, AI platforms like ChemPass are poised to accelerate the identification of promising compounds, dramatically shortening the early stages of drug development. The platform’s ability to generate and refine novel molecular structures based on specific biological targets will be critical in developing highly selective neutrophil modulators.
Systasy Bioscience, a German biotechnology company, will extend its innovative PathwayProfiler platform for functional profiling. Built on proprietary DNA barcoding technology, Systasy’s platform is designed to generate multiplexed functional data from stem cell-derived neutrophils. Induced pluripotent stem cells (iPSCs) offer an invaluable tool for disease modeling, allowing researchers to generate patient-specific cell types in vitro. By differentiating iPSCs into neutrophils, Systasy can create highly relevant human cellular models to test the efficacy and specificity of AI-designed drug candidates. The PathwayProfiler’s ability to provide high-dimensional readouts means it can capture a wealth of biological information about how compounds interact with neutrophils, enabling a comprehensive validation and refinement of the AI-designed candidates. This integration of advanced cellular models with computational design is crucial for ensuring that theoretical drug candidates translate into functional biological effects.
The Weizmann Institute of Science, a world-renowned multidisciplinary research institution in Rehovot, Israel, will provide critical support for high-throughput experimental validation. This involves rapidly screening a large number of compounds to confirm their predicted activity and selectivity. The institute’s expertise in automation and cutting-edge experimental methodologies will be seamlessly integrated with the computational design process, creating a feedback loop where experimental data informs and refines the AI models, leading to more effective and targeted drug design.
LMU University Hospital Munich, one of Europe’s largest and most reputable university hospitals, plays a pivotal role in bridging the gap between preclinical discovery and clinical application. Beyond providing the foundational scientific rationale through Professor Klein’s research, LMU will be responsible for validating lead compounds in sophisticated human in vitro neutrophil models. Their clinical expertise will also be instrumental in biomarker discovery, identifying measurable indicators of disease activity and treatment response, which are essential for clinical trials and patient stratification. Furthermore, LMU will guide the translational development, ensuring that promising compounds are advanced towards clinical testing in patients, drawing on their deep understanding of rare immunodeficiencies and broader inflammatory conditions.
EUREKA Grant: A Catalyst for Cross-Border Innovation
The backing of a prestigious EUREKA grant is a powerful endorsement of this collaboration’s potential and its innovative approach. EUREKA is a pan-European intergovernmental network that supports market-oriented international R&D and innovation projects. Its rigorous selection process ensures that funded projects are scientifically sound, technologically advanced, and possess strong market potential. Receiving this grant signifies a strong vote of confidence from a broad European scientific and economic community, acknowledging the uniqueness of the scientific rationale and the technological prowess of the partners, particularly Evogene’s ChemPass AI platform. Ofer Haviv, Evogene’s President and CEO, highlighted this, stating, "The support of the prestigious EUREKA grant is a strong vote of confidence in this synergistic collaboration, as well as further acknowledgment of the uniqueness of ChemPass AI." While financial terms of the grant were not disclosed, its provision underscores the strategic importance of this research in addressing critical health needs and fostering cross-border scientific advancement.
Evogene’s Expanding AI Horizon: A Chronology of Innovation
This collaboration with Systasy and LMU is part of a broader, highly productive period for Evogene, illustrating the company’s strategic commitment to expanding its footprint in AI-driven drug discovery. Just prior to this announcement, in January, Evogene unveiled a collaboration with Unravel Biosciences. This partnership aims to develop a first-in-class small-molecule therapy specifically designed to reverse neurological damage in demyelinating disorders, highlighting Evogene’s versatility in applying its AI platforms across various disease areas.
Further cementing its leadership in the nascent field of generative AI for life sciences, Evogene also announced an expanded partnership with Google Cloud in the same week as the LMU/Systasy collaboration. This enhanced alliance focuses on integrating advanced AI agents into the ChemPass AI platform, aiming to pioneer a generative AI foundation model for novel small-molecule design. Such a development promises to further augment ChemPass AI’s capabilities, making the drug discovery process even more efficient, intelligent, and capable of tackling increasingly complex biological challenges. These successive announcements paint a clear picture of Evogene’s strategic trajectory: leveraging state-of-the-art AI to accelerate the discovery and development of novel therapeutics across a spectrum of diseases, thereby positioning itself at the forefront of the AI-driven biopharma revolution.
Broader Impact and Future Outlook
The implications of this collaboration extend far beyond the immediate goal of developing new therapies for inflammatory diseases.
For Patients: The most direct and profound impact would be on patients suffering from chronic inflammatory conditions like IBD. A targeted therapy that can selectively modulate neutrophil activity without inducing broad immunosuppression would represent a paradigm shift. It promises not only more effective disease management but also a significant reduction in debilitating side effects associated with current treatments, leading to an improved quality of life, fewer hospitalizations, and potentially even disease remission for a larger patient population. This move towards precision medicine, tailored to specific immune pathways, embodies the future of therapeutic development.
For Drug Discovery and Development: This partnership serves as a compelling case study for the increasing integration of artificial intelligence and advanced biological platforms in drug discovery. The success of such a multidisciplinary, technology-driven approach could further validate AI’s potential to dramatically shorten discovery timelines, reduce costs, and improve the success rates of bringing new drugs to market. The drug discovery process is notoriously lengthy and expensive, with an average of 10-15 years and over $2 billion to bring a single drug from lab to patient. AI-driven platforms offer the promise of making this process more efficient and predictable.
For Immunology and Translational Medicine: The project’s foundation in understanding rare genetic immunodeficiencies and translating these insights into broader therapeutic strategies highlights the critical importance of translational research. It underscores how meticulous investigation into rare diseases can unlock fundamental biological mechanisms relevant to more common conditions. Furthermore, the collaboration’s focus on neutrophils could significantly advance our understanding of their precise roles in inflammatory pathology and open new avenues for targeted therapeutic interventions in a wider range of immune-mediated diseases.
Challenges and Prospects: While the promise is immense, the path to bringing a new drug to market is fraught with challenges. Rigorous preclinical validation, followed by extensive clinical trials across multiple phases, will be necessary to demonstrate safety and efficacy in human patients. Regulatory approvals will also be a significant hurdle. However, the comprehensive approach, bringing together AI-driven design, advanced cellular models, high-throughput validation, and deep clinical expertise, significantly strengthens the probability of success.
In conclusion, the alliance between Evogene, Systasy Bioscience, LMU University Hospital Munich, and the Weizmann Institute of Science represents a pivotal moment in the fight against inflammatory diseases. By harnessing the power of AI and leveraging profound biological insights, this collaboration is poised to deliver a new generation of targeted therapies, offering hope for millions affected by these debilitating conditions and charting a course for the future of precision drug discovery.
Leave a Reply